drugset
drugset / Trial / NCT02171767

Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male Volunteers

NCT02171767 ↗

Phase 1 Completed 48 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to assess pharmacokinetics incl. dose proportionality, safety and tolerability of 4 different dosage strengths of BIBW 2992 tablets (final formulation of 20 mg, 30 mg, 40 mg, 50 mg) administered as single doses to healthy male volunteers

Timeline

Start
2009-08
Primary completion
2009-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule 20 mg Oral
Subject Afatinib Small molecule 30 mg Oral
Subject Afatinib Small molecule 40 mg Oral
Subject Afatinib Small molecule 50 mg Oral

Indications

No indication recorded.